Company: INSP
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001609550-25-000032
Chunk: 72

Company: Inspire Medical Systems, Inc.
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 8
Chunk 72
---
 202,426 — — Total investments303,798 202,426 101,372 — Total cash equivalents and investments$386,932 $285,560 $101,372 $— 

13

Table of ContentsInspire Medical Systems, Inc. Notes to Consolidated Financial Statements (unaudited) (Table amounts in thousands, except share and per share amounts)

Fair Value Measurements as ofDecember 31, 2024EstimatedFair ValueLevel 1Level 2Level 3Cash equivalents:Money market funds$59,606 $59,606 $— $— Total cash equivalents59,606 59,606 — — Investments:Commercial paper19,831 — 19,831 — Corporate debt securities71,224 — 71,224 — Certificates of deposit7,694 — 7,694 — Asset-backed securities287 — 287 — U.S. government securities267,355 267,355 — — Total investments366,391 267,355 99,036 — Total cash equivalents and investments$425,997 $326,961 $99,036 $— There were no transfers between levels during the periods ended June 30, 2025 and December 31, 2024.Concentration of Credit RiskFinancial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash equivalents, investments, and accounts receivable. We maintain the majority of our cash and cash equivalents in accounts with major U.S. and multi-national financial institutions, and our deposits at certain of these institutions exceed insured limits. Market conditions can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we will be able to access uninsured funds in a timely manner or at all.Our investment policy limits investments to certain types of debt securities issued by the U.S. government and its agencies, corporations with investment-grade credit ratings, or commercial paper and money market funds issued by the highest quality financial and non-financial companies. We place restrictions on maturities and concentration by type and issuer. We are exposed to credit risk in the event of a default by the issuers of these securities to the extent recorded on the consolidated balance sheets. However, as of June 30, 2025 and December 31, 202